TOKYO--(BUSINESS WIRE)--CMIC Group, a pioneer and a leading CRO (Contract Research Organizations) in Japan, is pleased to announce that the company joined Align Clinical CRO, a life sciences industry standards group dedicated to creating open technology standards that make it easier for sponsors and contract research organizations (CROs) to work together during trials. CMIC is the first Japan-based CRO to join the group, bringing more than 25 years of solution provider experience and clinical trial operational expertise in Asia. CMIC is joining forces with leading CROs partners to improve execution and collaboration with life sciences companies during trials. With end-to-end solutions from preclinical to clinical, from drug development to manufacturing, and from filing to post marketing surveillance, CMIC is a strategic partner to help sponsors develop better medicine faster.
“The global healthcare industry is going through significant change. The types of service requests and qualification requirements are changing, the number of global trials is increasing, and study designs are more complex,” said Keiko Oishi, President and COO of CMIC HOLDINGS Co., Ltd. “As a member of Align Clinical CRO, CMIC is committed to helping the industry increase productivity, reduce operational costs, and run clinical trials more efficiently.”
For more information about CMIC clinical CRO services, please visit: https://www.cmicgroup.com/e/solution/clinical-studies
About Align Clinical CRO
Align Clinical CRO is an industry standards group founded by Veeva Systems and the world’s largest CROs. The group is dedicated to creating open technology standards that improve trial execution and collaboration with life sciences companies, making it easier for sponsors and CROs to work together during clinical trials. For more information, visit https://www.alignclinicalcro.org/
About CMIC Group
CMIC Group started business in 1992 as the first CRO in Japan, today the company provides comprehensive support services for the development, manufacturing, sales and marketing of pharmaceutical products. The company also operates to respond to diversifying needs by managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan drugs. CMIC Group has developed a unique business model called Pharmaceutical Value Creator (PVC) based on its abundant accumulated experience and knowledge as a CRO pioneer. CMIC Group utilizes the PVC to create new value in the healthcare field.
For more information, visit CMIC Group’s website: https://www.cmicgroup.com/e/